TriangleMirvetuximab Soravtansine (NCT07059845)
Mirvetuximab Soravtansine trial for Ovarian Cancer (NCT07059845). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with high-grade serous ovarian, fallopian-tube or primary peritoneal cancer meeting folate-receptor-alpha criteria. Groups cover first-line stage III–IV disease and platinum-sensitive recurrence, with different prior-treatment rules.
The idea: mirvetuximab delivers a cell-division-blocking payload to folate-receptor-bearing cells. Studies compare different doses with bevacizumab, carboplatin or both; one group receives bevacizumab alone. Carboplatin groups later receive mirvetuximab-based maintenance. All treatments are infused. Researchers measure response, progression and side effects, including eye problems. Prior folate-receptor-targeted treatment is excluded.
This phase 2 study plans 400 patients. AbbVie sponsors thirty recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.